A phase II trial (NCT04056910) of ivosidenib plus nivolumab (a fully human anti-PD-1 antibody) in patients with an advanced or refractory IDH1-mutant solid tumor, including CCA, demonstrated that all four patients with iCCA had stable disease (SD) [50]. This evidence concerns the gene IDH1 and cholangiocarcinoma.